It’s my bet they only supplied Pfizer during the pandemic cutting off dr-gs in phase trials, ki-ling the dr-g programs wholesale. In other words, destroying their sales pipeline, alienating researchers, blowing up trust. No wonder they don’t need... — read more 

Perhaps investors should look at one metric for the future growth of Croda, customer satisfaction. By the looks of the company’s news releases it has been since June 2022 that Croda has been awarded anything from a customer. In the June 2022... — read more 

Activist investor Standard Latitude, which recently disclosed a stake of just over 5%, could accelerate portfolio reviews and divestments. This makes Standard Latitude the 8th largest shareholder. Barclays has lifted its rating on Croda... — read more 

Shares dropped to 2514.00 during the day to mark yet another new low. With a forward PE ratio looking to shave another nine percent off the current PE ratio, no wonder another company hasn’t made a takeover bid. The best value is yet to come. The... — read more 

Better hope the business in Europe and Asia is robust. Then again, prescriptions are much less expensive there, probably not as profitable for Croda ‘Pharma’.

...Got himself a board of directors gig at Tate & Lyle. First foot is out the door. No pun intended. You read their press release and you wonder if they have paid attention to the past 4 years of Croda's share price. At least they can trust he... — read more 

Listen to the most recent earnings report for FY24. “Realigning our cost base.” "Benefits derived from payroll costs."

Thank you TheLayoff.com for creating this company’s home for real reporting by those affected by the ineffective management of a company that has seen its best days pass into the rearview mirror.